On September 25, 2025, Rocket Lab Corporation, a Delaware corporation (the "Company"), entered into a Stock Purchase Agreement (together with the ancillary documents thereto, the "Purchase Agreement"), by and among the Company, Rocket Lab USA, Inc., a Delaware corporation and wholly-owned subsidiary of the Company ("Buyer"), OC III LVS LIII LP, a Delaware limited partnership ("OC III") and CO Finance II LVS I LLC, a Delaware limited liability company ("COF II" and together with OC III, the "Sellers"), which provides for, among other things, Buyer's purchase and acquisition of all of the issued and outstanding ordinary shares of Mynaric AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of the Federal Republic of Germany ("Mynaric").
Pursuant to the terms of the Purchase Agreement, all of the issued and outstanding ordinary shares of Mynaric will be purchased in exchange for aggregate consideration of $75 million, consisting in cash or shares of the Company's common stock, $0.0001 par value ("Company Common Stock"), at the Company's discretion, subject to adjustments at closing (the "Transaction"). Additionally, the Purchase Agreement provides for up to $75 million in potential additional post-closing earnout payments to Sellers in cash or shares of Company Common Stock based on revenue targets of the Mynaric business for 2025, 2026 and 2027. The Company Common Stock issuable as stock consideration in the Transaction will be valued based on the volume weighted average price for the twenty (20) consecutive trading days ending on (and including) the trading day that is immediately preceding the day prior to the Closing Date (as defined in the Purchase Agreement) or the earnout payment date, as applicable.
All Comments